| 张 煜,李 坚,龚 杰,冯 健,鲍小京,张 能.心元胶囊联合曲美他嗪治疗冠心病心绞痛的临床研究[J].现代生物医学进展英文版,2020,(9):1741-1744. |
| 心元胶囊联合曲美他嗪治疗冠心病心绞痛的临床研究 |
| Clinical Study on Xinyuan Capsule Combined with Trimetazidine in the Treatment of Coronary Heart Disease Angina Pectoris |
| Received:August 23, 2019 Revised:September 18, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.09.030 |
| 中文关键词: 心元胶囊 曲美他嗪 冠心病心绞痛 临床研究 |
| 英文关键词: Xinyuan capsule Trimetazidine Coronary heart disease angina pectoris Clinical research |
| 基金项目:无锡市医学重点人才培养基金项目(ZDRC037) |
| Author Name | Affiliation | E-mail | | ZHANG Yu | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | zhangyu2685@163.com | | LI Jian | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | | | GONG Jie | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | | | FENG Jian | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | | | BAO Xiao-jing | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | | | ZHANG Neng | Department of Cardiovascular Medicine, Wuxi people's Hospital, Nanjing Medical University, Wuxi, Jiangsu, 214000, China | |
|
| Hits: 768 |
| Download times: 414 |
| 中文摘要: |
| 摘要 目的：探讨心元胶囊联合曲美他嗪治疗冠心病心绞痛的临床疗效及安全性。方法：选择2016年7月-2018年3月我院收治的冠心病心绞痛患者134例，按治疗方式分为对照组67例及观察组67例，对照组予以曲美他嗪治疗，观察组在对照组基础上予以心元胶囊治疗。比较分析两组患者疗效、心绞痛发作次数及持续时间、血清总胆固醇(TC)、甘油三酯(TG)、肿瘤坏死因子-α(TNF-α)、可溶性细胞黏附因子-1(sICAM-1)水平的变化及不良反应的发生情况。结果：治疗后，观察组和对照组临床总有效率分别为92.54%、79.10%，心电图总有效率分别为89.55%、76.12%，观察组均显著高于对照组两(P＜0.05)；两组心绞痛发作次数及持续时间均显著降低治疗前(P＜0.05)，且观察组显著低于对照组(P＜0.05)。观察组治疗后血清TC、TG、TNF-α、sICAM-1水平显著低于对照组(P＜0.05)。两组治疗过程中均未发生恶心、头晕头痛、心绞痛复发等不良反应。结论：心元胶囊联合曲美他嗪治疗心肾阴虚兼心血瘀阻证冠心病心绞痛患者可有效提升患者的临床疗效，其机制可能与改善血脂水平及降低炎症反应有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy and safety of Xinyuan capsule combined with trimetazidine in the treatment of angina pectoris of coronary heart disease. Methods: 134 patients with coronary heart disease and angina pectoris admitted to our hospital from July 2016 to March 2018 were divided into the control group (67 cases) and the observation group (67 cases) according to the treatment method. The control group was treated with trimetazidine, while the observation group was treated with Xinyuan capsule on the basis of the control group. The curative effect, the frequency and duration of angina pectoris, the changes of serum total cholesterol (TC), triglyceride (TG), tumor necrosis factor-α (TNF-α), soluble cell adhesion factor-1 (sICAM-1) and the occurrence of adverse reactions were compared between the two groups. Results: After treatment, the total clinical effective rate of observation group and the control group were 92.54%, 79.10% respectively, the total effective rate of electrocardiogram were 89.55% and 76.12% respectively, they were significantly higher in the observation group than those of the control group(P<0.05). The number and duration of angina attacks in both groups decreased significantly than those before treatment (P<0.05), which were significantly lower in the observation group than those in the control group (P<0.05). The levels of serum TC, TG, TNF-α and sICAM-1 in the observation group were significantly lower than those in the control group after treatment (P<0.05). There was no adverse reactions such as nausea, dizziness and headache, recurrence of angina pectoris in both groups. Conclusion: Xinyuan capsule combined with trimetazidine can effectively improve the clinical efficacy of patients with angina pectoris of coronary heart disease with deficiency of yin and blood stasis of heart and kidney, and its mechanism may be related to the improvement of blood lipid level and the decrease of inflammatory response. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
